Burn Insights and Trends

• The burn care landscape remains associated with a high clinical burden, driven by severe inflammatory, immune, and metabolic responses that can progress to shock, infection, organ failure, and long-term functional impairment, along with significant physical and psychological impact.
• Current management is centered on a combination of resuscitation, wound care, infection control, pain management, debridement, and surgical intervention, with treatment selection guided by burn depth and total body surface area (TBSA), which remain key determinants of outcomes and resource utilization.
• Despite advances in supportive care, limitations persist in achieving rapid wound closure, optimal scar outcomes, and full tissue regeneration, particularly in deep partial-thickness and full-thickness burns, where surgical intervention remains the mainstay of treatment.
• The approved advanced therapy landscape includes NexoBrid (enzymatic debridement), StrataGraft (regenerative skin substitute), and other cellular approaches such as RECELL and Epicel, reflecting a gradual shift toward biologically driven and tissue-preserving strategies.
• The emerging pipeline is increasingly focused on regenerative and tissue engineered solutions, including denovoSkin (CUTISS AG) and AGLE-102 (Aegle Therapeutics), aiming to improve skin regeneration, reduce donor-site dependence, and enhance long-term functional and cosmetic outcomes, though adoption will depend on clinical validation and regulatory success.
• Overall, while surgical grafting remains the gold standard, the burn treatment landscape is progressively evolving toward enzymatic debridement and regenerative medicine-based approaches, driven by unmet needs in healing speed, scarring reduction, and functional restoration.

Burn Market Size and Forecast in the 7MM

• 2025 Burn Market Size: ~USD 1,700 million
• 2036 Projected Burn Market Size: ~USD XX million
• Burn Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘Burn Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of the Burn, historical and forecasted epidemiology, as well as the Burn market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Burn market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, Burn patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022–2036) across global regions. The report highlights key unmet medical needs in Burn and maps the competitive and clinical landscape to uncover high‑value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Burn  Market

• Increasing Global Burden of Burn Injuries

The continued prevalence of thermal injuries, industrial accidents, electrical burns, and fire-related trauma is driving demand for effective burn management therapies. Severe burns often require prolonged wound care, infection control, and reconstructive interventions, creating a sustained need for advanced treatment options.

• High Unmet Need for Faster Healing and Improved Scar Outcomes

Delayed wound closure, hypertrophic scarring, and functional complications remain major challenges in burn recovery. This is accelerating development of therapies aimed at enhancing re-epithelialization, improving tissue regeneration, and reducing long-term scarring.

• Rising Burn Wound Infections and Antimicrobial Resistance

Loss of skin barrier integrity after burns increases susceptibility to bacterial colonization and infection. Growing concerns around antimicrobial-resistant pathogens are driving demand for novel antimicrobial strategies and improved infection management approaches.

• Expansion of Regenerative and Biologic Therapies

Advances in stem cell therapies, extracellular vesicles, growth factors, and bioengineered approaches are creating new opportunities to enhance angiogenesis, modulate inflammation, and improve burn wound regeneration.

Burn Understanding

Burn Overview and Diagnosis

Burns are traumatic injuries involving damage to the skin and underlying tissues caused by thermal, chemical, electrical, radiation, or other sources. Burn severity is classified based on depth (superficial, partial-thickness, and full-thickness) and extent of injury, including total body surface area (TBSA) involvement. Severe burns are associated with tissue necrosis, inflammation, immune dysfunction, infection risk, delayed wound healing, and scarring. Despite advances in wound care, debridement, infection management, and reconstructive procedures, significant unmet needs remain due to complications such as hypertrophic scarring, contractures, and impaired quality of life, driving development of advanced burn therapies focused on improving healing and tissue regeneration.

Diagnosis of burns is primarily based on assessment of injury depth, total body surface area (TBSA) involvement, and severity to guide treatment decisions. Evaluation includes a detailed history of the mechanism of injury, burn source, timing, and associated trauma, followed by clinical examination to assess wound characteristics, burn depth, anatomical location, and complications such as inhalation injury or infection. Additional investigations may be performed in severe cases to evaluate systemic involvement. Accurate burn assessment is essential for guiding resuscitation, debridement, wound management, infection control, and reconstructive strategies, while reducing complications such as delayed healing, scarring, and functional impairment.

Further details are provided in the report.

Burn Treatment 

Treatment of burns focuses on stabilization, wound healing, infection prevention, pain control, and functional recovery while reducing complications such as scarring and contractures. Management is based on burn depth, total body surface area (TBSA) involvement, injury location, and overall clinical status. Initial care includes fluid resuscitation, temperature control, analgesia, and assessment of associated injuries such as inhalation injury. Burn wound management involves cleaning, debridement, topical antimicrobial therapy when indicated, appropriate dressings, and wound coverage strategies to support healing and prevent infection. Advanced approaches, including enzymatic debridement, regenerative therapies, and surgical excision with skin grafting, may be used for deeper or extensive burns.

Further details related to country-based variations are provided in the report.

Burn Unmet Needs

The section “unmet needs of Burn” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress. 

1. Delayed onset of current pharmacological therapies
2. High burden of hypertrophic scarring and contracture formation
3. Increasing challenges in burn wound infection management and antimicrobial resistance
4. Need for safer and more effective alternatives to surgical debridement and grafting, and others…..

Note: Comprehensive unmet needs insights in Burn and their strategic implications are provided in the full report.

Burn Epidemiology

Key Findings from Burn Epidemiological Analysis and Forecast 

• According to DelveInsight’s analysis, The total Incident cases of burn injury in the 7MM were ~ 5,497,000 cases in 2025. 
• Among EU4 and the UK, the highest Incident cases of Burn injury that require medical treatment were recorded in the UK (~285,900) followed by France (~205,000), in 2025. On the other hand, Italy accounted for the least cases, approximately 120,000 in 2025.
• On the basis of severity, burns was bifurcated into First-degree, Second-degree, Third-degree, and Unspecified. In EU4 and the UK, Second-degree burns accounted for the maximum number of cases, which was approximately 768,000.
• In the United States, among etiology-specific cases 41% cases were due to flame, 31% cases were of scald, 9% cases of contact, 4% cases of electrical, 4% cases of chemical and 12% cases were of other burn.
• Japan recorded an estimated ~330,000 burn injury cases requiring medical treatment in 2025.

Burn Drug Analysis & Competitive Landscape

The Burn drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I/II–III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the Burn treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the Burn therapeutics market.

Approved Therapies for Burn

Anacaulase-bcdb (NEXOBRID): MediWound

NexoBrid is MediWound’s FDA-approved enzymatic debridement therapy developed for the removal of eschar in deep partial-thickness and full-thickness thermal burns. The therapy addresses a key unmet need in burn care by providing a non-surgical, selective eschar removal approach, aiming to reduce reliance on surgical debridement and support effective wound-bed preparation. 

Following commercialization, NexoBrid has demonstrated increasing adoption in the U.S. burn care setting, with Vericel reporting expanding utilization across more than 70 burn centers and continued growth in product uptake. MediWound has also expanded manufacturing capacity to support anticipated global demand, reflecting increasing commercial focus on enzymatic burn management.

Note: Detailed marketed therapies assessment will be provided in the final report.

Burn Pipeline Analysis

DenovoSkin: CUTISS

DenovoSkin being developed by CUTISS, is bio-engineered within large quantities (>1:100) with a thick, double layer, robust structure. DenovoSkin is a patented, personalized, autologous bio-engineered human skin graft classified as Advanced Therapy Medical Product (ATMP). In parallel, CUTISS is advancing denovoSkin in an ongoing Phase III clinical trial for adolescents and adults with severe burns across the EU and Switzerland.

MW-III: Skingenix

MW-III is a topical product being evaluated for second-degree burns in adult patients. The drug is a botanical drug product developed for treating burns and other cutaneous wounds, which will be made from natural ingredients. In February 2023, the first patient was treated with Skingenix's investigational drug MW-III in a Phase II trial at MedStar Washington Hospital Center, led by Dr. Jeffrey Shupp. Currently, the drug is in Phase II study (NCT01297400) of the clinical trial. 

Note: Detailed emerging therapies assessment will be provided in the final report.

Burn Key Players, Market Leaders and Emerging Companies

• Vericel Corporation
• Skingenix
• Aegle Therapeutics
• CUTISS, and others

Burn Drug Updates

• In March 2026, CUTISS announced publication of 1-year Phase II results for denovoSkin in reconstructive surgery, reporting favorable safety and clinical outcomes with the bioengineered dermo-epidermal skin substitute.
• In May 2025, CUTISS completed an interim analysis of its Phase II clinical trial evaluating the safety and efficacy of DenovoSkin in pediatric patients with severe burns. The analysis confirmed a favorable safety profile and demonstrated promising signals of efficacy, supporting the continued clinical development of denovoSkin for pediatric burn treatment.
• In January 2024, Aegle Therapeutics announced positive 12-week data for the first patient enrolled in a Phase I/IIa clinical trial of AGLE-102 for the treatment of severe second-degree burns. The patient achieved 99% epithelialization of the burn wound and had a significant reduction in edema within seven days of treatment. Subsequent doses of AGLE-102 were not required.

Drug Class Insights

Burn Market Outlook

The current burn treatment landscape focuses on wound stabilization, infection prevention, tissue preservation, and restoration of skin function, with management determined by burn severity, depth, and TBSA involvement. Standard care includes fluid resuscitation, pain management, wound care, topical antimicrobials, debridement, and surgical intervention. However, conventional therapies largely support wound management and have limited ability to achieve true tissue regeneration.

For severe burns, early excision followed by autologous split-thickness skin grafting (STSG) remains the standard of care, but limitations such as donor-site scarcity, surgical burden, scarring, and contracture formation continue to drive unmet need.

Advanced treatment options include NexoBrid, a bromelain-based enzymatic debridement biologic medicinal product used for selective burn eschar removal, and StrataGraft, a bioengineered allogeneic cellular/tissue-based skin substitute for deep partial-thickness burns. Additional technologies such as RECELL, a cell-harvesting and processing medical device that generates autologous spray-on skin cells, Epicel (cultured epidermal autograft, a cell-based therapy aim to improve wound closure outcomes and reduce reliance on conventional grafting procedures.

The burn market is shifting toward regenerative medicine, tissue-engineered skin substitutes, and cell-based therapies. Emerging assets such as denovoSkin (CUTISS AG), an autologous bioengineered dermo-epidermal skin substitute, are being developed to support skin regeneration and address limitations of current grafting approaches. denovoSkin is advancing in Phase III clinical development for severe burns in adults and adolescents in Switzerland and the European Union and has received Orphan Drug Designation from Swissmedic, EMA, and the FDA. AGLE-102 (Aegle Therapeutics), an extracellular vesicle-based regenerative therapy derived from allogeneic mesenchymal stem cells, represents another emerging approach targeting tissue repair and inflammatory modulation. 

Further details will be provided in the report….

Drug Class/Insights into Leading Emerging and Marketed Therapies in Burn (2022–2036 Forecast)

The Burn treatment landscape comprises antidepressants, anxiolytics, adjunctive agents, and emerging novel therapies, each targeting different aspects of neurotransmitter imbalance and symptom control.

• Enzymatic Debridement Agents: Therapies such as anacaulase-bcdb (NexoBrid) act by enzymatically degrading burn eschar through proteolytic activity, enabling selective removal of non-viable tissue while preserving viable wound structures. 
• Regenerative Skin Substitutes: Therapies such as StrataGraft and denovoSkin are designed to restore damaged skin architecture by providing cellular or bioengineered skin components that support skin regeneration, tissue repair, and wound closure.

Burn Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the Burn drug’s uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of therapies in the burn market is expected to vary across standard surgical approaches, approved advanced therapies, and emerging regenerative technologies. Autologous split thickness skin grafting (STSG) is expected to remain the standard of care due to established clinical experience, while advanced therapies such as NexoBrid and StrataGraft may see increasing adoption due to their ability to address limitations of conventional burn management through enzymatic debridement and regenerative skin replacement approaches.

Emerging therapies such as denovoSkin (CUTISS AG) and AGLE-102 (Aegle Therapeutics) are expected to gain gradual adoption as clinical data mature, driven by their potential to improve skin regeneration, reduce surgical burden, and address unmet needs such as donor-site limitations and scarring.

Detailed insights of emerging therapies' drug uptake is included in the report.

Market Access and Reimbursement of Burn 

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

NOTE: Further Details are provided in the final report….

Burn Therapies Price Scenario & Trends 

Pricing and analogue assessment of Burn therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Further details are provided in the final report….

Industry Experts and Physician Views for Burn 

To keep up with Burn market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the Burn emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in Burn, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights at country level. Centers such as the USDA Forest Service, Pacific Southwest Research Station, Department of Plastic and Reconstructive Surgery, Germany, and Department of Trauma and Critical Care Medicine, Tokyo, Japan, etc. were contacted.Their opinion helps understand and validate current and emerging Burn therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in Burn.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis. 

In the SWOT analysis of Burn, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided. 

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of Burn, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Burn market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Burn market. 

Report Insights

• Burn Patient Population Forecast
• Burn Therapeutics Market Size 
• Burn Pipeline Analysis
• Burn Market Size and Trends
• Burn Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report 
• 11-Year Forecast 
• Burn Market Outlook (North America, Europe, Asia-Pacific) 
• Patient Burden Trends (By Geography)
• Burn Treatment Addressable Market (TAM)
• Burn Competitve Landscape
•  Burn Major Companies Insights
• Burn Price Trends and Analogue Assessment
• Burn Therapies Drug Adoption/Uptake
• Burn Therapies Peak Patient Share Analysis

Report Assessment

• Burn Current Treatment Practices
• Burn Unmet Needs
• Burn Clinical Development Analysis
• Burn Emerging Drugs Product Profiles
• Burn Market attractiveness
• Burn Qualitative Analysis (SWOT and conjoint analysis)

FAQs

Market Insights

• What was the Burn market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Burn?
• What are the disease risks, burdens, and unmet needs of Burn? What will be the growth opportunities across the 7MM concerning the patient population with Burn?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Burn? What are the current guidelines for treating Burn in the US, Europe, and Japan?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Burn market.
• Bottom-up forecasting builds from the affected population to product forecasts, delivering a robust, data-driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)-enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data-driven decisions.